Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.79 |
| ▸ | ACE | P12821 | 4/20 | 0.79 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.46 |
| ▸ | GRN | P28799 | 3/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ore-1001 SCHEMBL9993284 | 0.89 | ACE2 (1.00) | ACE2ACECYP11B1CYP11B2GRN | |
| Ore-1001 SCHEMBL9992978 | 0.89 | ACE2 (1.00) | ACE2ACECYP11B1CYP11B2GRN | |
| Ore-1001 SCHEMBL5869286 | 0.89 | ACE2 (1.00) | ACE2ACECYP11B1CYP11B2GRN | |
| Ore-1001 SCHEMBL9994114 | 0.89 | ACE2 (1.00) | ACE2ACECYP11B1CYP11B2GRN | |
| Ore-1001 SCHEMBL5869293 | 0.89 | ACE2 (1.00) | ACE2ACECYP11B1CYP11B2GRN | |
| Ore-1001 SCHEMBL1691048 | 0.89 | ACE2 (1.00) | ACE2ACECYP11B1CYP11B2GRN | |
| Ore-1001 SCHEMBL2223815 | 0.89 | ACE2 (1.00) | ACE2ACECYP11B1CYP11B2GRN | |
| Ore-1001 SCHEMBL1656029 | 0.89 | ACE2 (1.00) | ACE2ACECYP11B1CYP11B2GRN | |
| Ore-1001 SCHEMBL1691045 | 0.89 | ACE2 (1.00) | ACE2ACECYP11B1CYP11B2GRN | |
| SCHEMBL5870470 | 0.87 | ACE2 (0.78) | ACE2ACECYP11B1CYP11B2GRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ACE2 2/4885ACE 1/4885CYP11B1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.